191 related articles for article (PubMed ID: 10708435)
1. A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates.
Bailly JE; McAuliffe JM; Durbin AP; Elkins WR; Collins PL; Murphy BR
J Virol; 2000 Apr; 74(7):3188-95. PubMed ID: 10708435
[TBL] [Abstract][Full Text] [Related]
2. Sequence determination and molecular analysis of two strains of bovine parainfluenza virus type 3 that are attenuated for primates.
Bailly JE; McAuliffe JM; Skiadopoulos MH; Collins PL; Murphy BR
Virus Genes; 2000; 20(2):173-82. PubMed ID: 10872880
[TBL] [Abstract][Full Text] [Related]
3. Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic.
Skiadopoulos MH; Schmidt AC; Riggs JM; Surman SR; Elkins WR; St Claire M; Collins PL; Murphy BR
J Virol; 2003 Jan; 77(2):1141-8. PubMed ID: 12502830
[TBL] [Abstract][Full Text] [Related]
4. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.
Schmidt AC; McAuliffe JM; Huang A; Surman SR; Bailly JE; Elkins WR; Collins PL; Murphy BR; Skiadopoulos MH
J Virol; 2000 Oct; 74(19):8922-9. PubMed ID: 10982335
[TBL] [Abstract][Full Text] [Related]
5. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
[TBL] [Abstract][Full Text] [Related]
6. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
[TBL] [Abstract][Full Text] [Related]
7. Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector.
Haller AA; Miller T; Mitiku M; Coelingh K
J Virol; 2000 Dec; 74(24):11626-35. PubMed ID: 11090161
[TBL] [Abstract][Full Text] [Related]
8. A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys.
Skiadopoulos MH; Surman SR; Riggs JM; Collins PL; Murphy BR
J Virol; 2001 Nov; 75(21):10498-504. PubMed ID: 11581420
[TBL] [Abstract][Full Text] [Related]
9. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
[TBL] [Abstract][Full Text] [Related]
10. Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells.
Nelson CL; Tang RS; Stillman EA
Vaccine; 2013 Aug; 31(36):3756-62. PubMed ID: 23623857
[TBL] [Abstract][Full Text] [Related]
11. A single amino acid substitution in the viral polymerase creates a temperature-sensitive and attenuated recombinant bovine parainfluenza virus type 3.
Haller AA; MacPhail M; Mitiku M; Tang RS
Virology; 2001 Sep; 288(2):342-50. PubMed ID: 11601905
[TBL] [Abstract][Full Text] [Related]
12. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.
Lee MS; Greenberg DP; Yeh SH; Yogev R; Reisinger KS; Ward JI; Blatter MM; Cho I; Holmes SJ; Cordova JM; August MJ; Chen W; Mehta HB; Coelingh KL; Mendelman PM
J Infect Dis; 2001 Oct; 184(7):909-13. PubMed ID: 11509996
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
Durbin AP; Cho CJ; Elkins WR; Wyatt LS; Moss B; Murphy BR
J Infect Dis; 1999 Jun; 179(6):1345-51. PubMed ID: 10228053
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates.
Durbin AP; McAuliffe JM; Collins PL; Murphy BR
Virology; 1999 Sep; 261(2):319-30. PubMed ID: 10497117
[TBL] [Abstract][Full Text] [Related]
15. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys.
Durbin AP; Wyatt LS; Siew J; Moss B; Murphy BR
Vaccine; 1998 Aug; 16(13):1324-30. PubMed ID: 9682397
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.
Karron RA; Thumar B; Schappell E; Surman S; Murphy BR; Collins PL; Schmidt AC
Vaccine; 2012 Jun; 30(26):3975-81. PubMed ID: 22178099
[TBL] [Abstract][Full Text] [Related]
17. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.
Durbin AP; Skiadopoulos MH; McAuliffe JM; Riggs JM; Surman SR; Collins PL; Murphy BR
J Virol; 2000 Aug; 74(15):6821-31. PubMed ID: 10888621
[TBL] [Abstract][Full Text] [Related]
18. A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys.
Tang RS; Mahmood K; Macphail M; Guzzetta JM; Haller AA; Liu H; Kaur J; Lawlor HA; Stillman EA; Schickli JH; Fouchier RA; Osterhaus AD; Spaete RR
Vaccine; 2005 Feb; 23(14):1657-67. PubMed ID: 15705469
[TBL] [Abstract][Full Text] [Related]
19. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.
Tao T; Durbin AP; Whitehead SS; Davoodi F; Collins PL; Murphy BR
J Virol; 1998 Apr; 72(4):2955-61. PubMed ID: 9525616
[TBL] [Abstract][Full Text] [Related]
20. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
Tao T; Skiadopoulos MH; Davoodi F; Riggs JM; Collins PL; Murphy BR
J Virol; 2000 Jul; 74(14):6448-58. PubMed ID: 10864657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
